choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Multaq

Multaq Newsletter
  • Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER 28 Apr 2021 05:30 GMT

    … dexamethasone for the treatment of adult patients … Orphan Medicinal Products (COMP) granted Orphan Drug Designation … to COVID-19 vaccines Sanofi will support manufacturing and … First Quarter 2021 Pharmaceuticals Vaccines Consumer Healthcare Others(1) …

  • Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER 05 Feb 2021 06:30 GMT

    … bringing breakthrough medicines and vaccines to people … drug designation from the FDA for the treatment … -initiated Phase 3 trials. FDA has designated SAR442257, … Sanofi) on May 29th 2020. Full-year 2020 Pharmaceuticals Consumer Healthcare Vaccines

  • Sanofi Q3 2020 business EPS(1) growth of 8.8% at CER 29 Oct 2020 06:30 GMT

    … will deliver promising medicines to address significant … orphan drug designation by the FDA for the treatment of … of the vaccine, including clinical trials, with the … Sanofi) on May 29th 2020. 9 Months 2020 Pharmaceuticals Consumer Healthcare Vaccines

  • Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation 29 Jul 2020 05:30 GMT

    trial and the Sanofi-led trialMedical Products Administration (NMPA) in China approved Dupixent® (dupilumab) for the treatment … Food and Drug Administration (FDA) approved … Sanofi) on May 29th 2020. Half Year 2020 Pharmaceuticals Consumer Healthcare Vaccines

  • EMA recommends restriction of heart drug Multaq 04 Aug 2020 11:21 GMT

    … . Now, the European Medicines Agency’s Committee for Medicinal Products for Human … the use of Multaq. As per the suggestion, this drug should be … . Only after considering other treatment options, Multaq may be prescribed owing to …

  • Sanofi at forefront of fight against COVID-19 in Q1 2020 24 Apr 2020 05:30 GMT

    trial programs and to advance our pipeline of potentially transformative medicines … . Food and Drug Administration (FDA), in combination … equity accounting treatment of Sanofi’s ownership … Quarter 2020 Pharmaceuticals Consumer Healthcare Vaccines Others(2) …

  • Sanofi delivers strong 2019 business EPS growth of 6.8% at CER 06 Feb 2020 06:30 GMT

    … Care, General Medicines and Vaccines together with a … S. Food and Drug Administration (FDA) and Health … clinical trials evaluating olipudase alfa for the treatment … , Sanofi Business Services, etc…). 2019 Pharmaceuticals Consumer Healthcare Vaccines Others …

  • Sanofi Q3 well on track 31 Oct 2019 06:30 GMT

    … with previous clinical trials and sustained efficacy. … S. Food and Drug Administration (FDA) and Health … to develop transformative treatments for patients while … Sanofi Business Services, etc…). Nine Months 2019 Pharmaceuticals Consumer Healthcare Vaccines

  • Sanofi delivered solid growth in Q2 2019 29 Jul 2019 05:30 GMT

    … . Food and Drug Administration (FDA) accepted for … plus another medicinal product for maintenance treatment. In May … three Phase 3 trials of ZynquistaTM (sotagliflozin … Sanofi Business Services, etc…). Half year 2019 Pharmaceuticals Consumer Healthcare Vaccines

  • Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER 26 Apr 2019 05:31 GMT

    medicinal product for maintenance treatment. In the first quarter, the U.S. FDA … phase 3 trials evaluating Dupixent® in … therapeutic alternatives, Sanofi';s ability to … First quarter 2019 Pharmaceuticals Consumer Healthcare Vaccines Others (1) Total Group …

Satisfied with the content?

Continue to create your account.